PET/CT and MR imaging in myeloma

[1]  U. Exner,et al.  PET-positive fibrous dysplasia - a potentially misleading incidental finding in a patient with intimal sarcoma of the pulmonary artery , 2007, Skeletal Radiology.

[2]  B. Line,et al.  Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma , 2006, Skeletal Radiology.

[3]  Abraham Schneider,et al.  Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Resnick,et al.  Magnetic resonance imaging of para-acetabular insufficiency fractures in patients with malignancy. , 2006, Clinical radiology.

[5]  P. Loehrer,et al.  International Staging System for Multiple Myeloma , 2006 .

[6]  E. Kotter,et al.  Whole-body MRI in the detection of bone marrow infiltration in patients with plasma cell neoplasms in comparison to the radiological skeletal survey , 2006, European Radiology.

[7]  G. Morgan,et al.  Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Bladé,et al.  Renal, hematologic and infectious complications in multiple myeloma. , 2005, Best practice & research. Clinical haematology.

[9]  R. Fietkau,et al.  Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates? , 2005, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery.

[10]  P. Kuo,et al.  Artifactual spinal metastases imaged by PET/CT: a case report. , 2005, Journal of nuclear medicine technology.

[11]  B. Barlogie,et al.  18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Mulligan.  Imaging techniques used in the diagnosis, staging, and follow-up of patients with myeloma , 2005, Acta radiologica.

[13]  D. Podoloff,et al.  Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  B. Barlogie,et al.  Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  S. Raman,et al.  Whole-body PET/CT: Spectrum of physiological variants, artifacts and interpretative pitfalls in cancer patients , 2005, Nuclear medicine communications.

[16]  H. Kauczor,et al.  Dynamic contrast‐enhanced MRI for assessing the disease activity of multiple myeloma: A comparative study with histology and clinical markers , 2005, Journal of magnetic resonance imaging : JMRI.

[17]  D. Peterson,et al.  Bisphosphonate‐associated osteonecrosis of mandibular and maxillary bone , 2005, Cancer.

[18]  Gary Caputo,et al.  Value of FDG PET in the assessment of patients with multiple myeloma. , 2005, AJR. American journal of roentgenology.

[19]  M. Reiser,et al.  Role of MRI for the diagnosis and prognosis of multiple myeloma. , 2005, European journal of radiology.

[20]  F. Sim,et al.  Effect of granulocyte-stimulating factors on marrow of adult patients with musculoskeletal malignancies: incidence and MRI findings. , 2004, AJR. American journal of roentgenology.

[21]  G. Cook,et al.  Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging. , 2004, Seminars in nuclear medicine.

[22]  F. Zhan,et al.  The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. , 2003, The New England journal of medicine.

[23]  G. Morgan,et al.  Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. , 2003, The hematology journal : the official journal of the European Haematology Association.

[24]  H. Schirrmeister,et al.  Positron emission tomography (PET) for staging of solitary plasmacytoma. , 2003, Cancer biotherapy & radiopharmaceuticals.

[25]  S. Chen‐Kiang.  Plasma cells and multiple myeloma , 2003 .

[26]  M. Castillo.  Diffusion-weighted imaging of the spine: is it reliable? , 2003, AJNR. American journal of neuroradiology.

[27]  Kenneth C. Anderson,et al.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group , 2003, British journal of haematology.

[28]  A. Waxman,et al.  Whole-body (18)F-FDG PET identifies high-risk myeloma. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  P. Conti,et al.  Diagnostic utility of FDG PET in multiple myeloma , 2002, Skeletal Radiology.

[30]  N. Malliaraki,et al.  Correlation between the uptake of Tc-99m-sestaMIBI and prognostic factors in patients with multiple myeloma. , 2002, Clinical and laboratory haematology.

[31]  R W Günther,et al.  Multidetector CT of the spine in multiple myeloma: comparison with MR imaging and radiography. , 2002, AJR. American journal of roentgenology.

[32]  J. Michaeli,et al.  Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J Shaughnessy,et al.  Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. , 2001, Blood.

[34]  M. Reiser,et al.  Diagnostic value of increased diffusion weighting of a steady-state free precession sequence for differentiating acute benign osteoporotic fractures from pathologic vertebral compression fractures. , 2001, AJNR. American journal of neuroradiology.

[35]  S. Dechambre,et al.  Bone marrow transplantation in patients with multiple myeloma: prognostic significance of MR imaging. , 2001, AJR. American journal of roentgenology.

[36]  B. Barlogie,et al.  Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. , 2000, Blood.

[37]  M. Mulligan.  Myeloma and lymphoma. , 2000, Seminars in musculoskeletal radiology.

[38]  B. Maldague,et al.  Skeletal survey in advanced multiple myeloma: radiographic versus MR imaging survey , 1999, British journal of haematology.

[39]  John L. Humm,et al.  Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. , 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[40]  B. Maldague,et al.  Treated plasma cell lesions of bone with MRI signs of response to treatment: unexpected pathological findings , 1998, Skeletal Radiology.

[41]  D. Bihan,et al.  Differentiation of benign versus pathologic compression fractures with diffusion-weighted MR imaging: a closer step toward the "holy grail" of tissue characterization? , 1998 .

[42]  N. Howarth,et al.  Role of MRI in the diagnosis of insufficiency fractures of the sacrum and acetabular roof , 1997, Skeletal Radiology.

[43]  A Ferrant,et al.  Vertebral compression fractures in multiple myeloma. Part I. Distribution and appearance at MR imaging. , 1997, Radiology.

[44]  J. Laredo,et al.  Acute vertebral collapse: CT findings in benign and malignant nontraumatic cases. , 1995, Radiology.

[45]  M. Dimopoulos,et al.  Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  S. Salmon,et al.  A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.

[47]  G. Edelstyn,et al.  The radiological demonstration of osseous metastases. Experimental observations. , 1967, Clinical radiology.

[48]  S. Jasko,et al.  Therapy , 1881, The American journal of dental science.